Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00160706 · ClinicalTrials.gov registry record · Phase 3

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

A Phase 3 study of Crohn's Disease, sponsored by UCB Pharma.

Completed
Registry status
Phase 3
Development phase
310
Enrollment target
20
Study locations

NCT00160706 is a Phase 3 study of Crohn's Disease that has completed, run by UCB Pharma. The registered enrollment target is 310 participants, below the 2,412-participant average among 104 other Crohn's Disease trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00160706, a Phase 3 study of Crohn's Disease, has completed, sponsored by UCB Pharma.

COMPLETED
Registry status
Phase 3
Development phase
310 participants
Enrollment target
20
Study locations

Study Summary

A follow-on safety study in subjects with Crohn's Disease who have previously been withdrawn from the double-blind study CDP870-031 \[NCT00152490\] or CDP870-032 \[NCT00152425\] due to an exacerbation of Crohn's Disease.

Conditions Studied

Crohn's Disease

Interventions

  • BIOLOGICAL Certolizumab Pegol (CDP870)

Study Locations (20)

Florida

  • 45094 - Gainesville
  • 45005 - Hialeah
  • 45087 - Miami
  • 45004 - North Miami Beach

Alabama

  • 45102 - Birmingham
  • 45028 - Huntsville

California

  • 45095 - Orange
  • 45101 - San Francisco

Maryland

  • 45033 - Chevy Chase
  • 45013 - Laurel

New York

  • 45009 - Great Neck
  • 45070 - New York

Arkansas

  • 45044 - Little Rock

Colorado

  • 45130 - Colorado Springs

Illinois

  • 45016 - Chicago

Trial Details

FieldValue
Enrollment Target 310 participants
Start Date 2004-02
Est. Completion 2012-05
Phase Phase 3

Sponsor

UCB Pharma

100 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00160706

The ClinicalTrials.gov registry entry for NCT00160706 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,412-participant average among 104 other Crohn's Disease trials with a reported enrollment target (87% lower). The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Certolizumab Pegol (CDP870) is the first listed.

NCT00160706 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT00160706 about?

NCT00160706 is a clinical study titled "A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease". A follow-on safety study in subjects with Crohn's Disease who have previously been withdrawn from the double-blind study CDP870-031 \[NCT00152490\] or CDP870-032 \[NCT00152425\] due to an exacerbation of Crohn's Disease.

What is the current status of trial NCT00160706?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 310 participants. The study started on 2004-02. Estimated completion is 2012-05.

What conditions does trial NCT00160706 study?

This clinical trial studies the following conditions: Crohn's Disease.

What interventions are being tested in trial NCT00160706?

The interventions under investigation include: Certolizumab Pegol (CDP870) (BIOLOGICAL).

Who is sponsoring clinical trial NCT00160706?

This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00160706 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Crohn's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Crohn's Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.